Amgen management check

AMGN · Health Care · Biotechnology · CEO Mr. Bradway

Filings as of

76
Management score, ranked 111th of 487 · 11th of 60 in Health Care4 good · 3 to watch · 0 flaggedStrongest: stable leadership · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Watch

    Have owners done well?

    Trailed its chosen peersOwners$167Peers$192

    What $100 became since fiscal 2021

    3339th
    Detail

    $100 invested at the start of fiscal 2021 grew to $167, against $192 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    8352nd
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.67 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.3% of net income

    $24.7m pay · $7.7bn net income, FY2025

    0.1%1%3%10%
    9188th
    Detail

    $24.7m of reported pay in fiscal 2025, against $7.7bn of net income.

  • Watch

    Do they own the stock?

    Insiders are selling

    6 mo: ▲ $0 bought · ▼ $4.1m sold

    ——
    Detail

    3 insiders sold $4.1m in the last six months and none bought.

  • Watch

    Are owners being diluted?

    Share count growing2021 · 573m2025 · 542m

    Diluted shares +0.4% a year; flagged above +2%

    0%10%20%

    Stock pay 1.3% of revenue

    4526th
    Detail

    Diluted shares changed +0.4% a year over the last three fiscal years. Stock-based pay was 1.3% of revenue in the latest year.

  • Good

    Is leadership stable?

    5 leadership filings in 3 years

    5 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Mr. Bradway

    100100th
    Detail

    CEO in the pay table: Mr. Bradway. 5 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 7, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$24.7m$49.4m$10020212022202320242025$167$192

Pay tied most to non-GAAP, earnings per share, or EPS

Other key measuresNon-GAAP earnings per share (EPS)Non-GAAP return on invested capital (ROIC)Total shareholder return (TSR) relative to that of the S&P 500RevenuesNon-GAAP net incomePipeline, clinical study, and regulatory goalsWorkforce and technology goals

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Bradway$24.7m$49.4m$8.5m$167$192$7.7bn
2024—$24.4m$12.7m$9.8m$129$150$4.1bn
2023—$22.6m$29.1m$7.7m$138$138$6.7bn
2022—$21.4m$41.7m$7.2m$121$136$6.6bn
2021—$21.7m$17.0m$7.4m$101$123$5.9bn

Insiders and the CEO's stakeSelling

3 insiders sold $4.1m in the last six months and none bought.

Open-market trades by officers and directors since May 21, 2026.

  • SoldDerek MillerSVP, Human Resources$1.6mAug 6, 2026
  • SoldRachna KhoslaSVP, Business Development$1.3mAug 13, 2026
  • SoldNancy A. GrygielSVP & CCO$1.2mAug 6, 2026

Leadership and governance on file

20222023202420252026Leadership 7Votes 5
All 7 filings

Latest shareholder vote results: May 20, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $34.3bn returned to owners in buybacks and dividends, 111% of net income, and $2.2bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$5.3bn$10.6bn20212022202320242025Shares573m541m538m541m542m
Show the figures
Fiscal year20212022202320242025
Revenue$26.0bn$26.3bn$28.2bn$33.4bn$36.8bn
Net income$5.9bn$6.6bn$6.7bn$4.1bn$7.7bn
Stock-based pay$341.0m$401.0m$431.0m$530.0m$494.0m
Buybacks$5.0bn$6.4bn$0$200.0m$0
Dividends$4.0bn$4.2bn$4.6bn$4.8bn$5.1bn
Diluted shares573m541m538m541m542m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.